Integra LifeSciences Holdings (IART)
$16.72
$0.28
(1.70%)
As on 04-Sep-2026 16:00EDT
Market cap
$1,300 Mln
Revenue (TTM)
$1,648 Mln
P/E Ratio
--
P/B Ratio
1.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0 %
-
ROCE
-- %
-
Industry P/E
46.09
-
EV/EBITDA
12.6
-
Debt to Equity
1.7
-
Book Value
$13.4
-
EPS
$-0.1
-
Face value
--
-
Shares outstanding
77,772,506
10 Years Aggregate
CFO
$1,898.94 Mln
EBITDA
$1,724.94 Mln
Net Profit
$832.05 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Integra LifeSciences Holdings (IART)
| 34.6 | -6.5 | 3.9 | 10.5 | -26.9 | -26.1 | -9.1 |
|
BSE Sensex*
| -9.9 | -3.4 | 2.7 | -5.5 | 5.0 | 5.5 | 10.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Integra LifeSciences Holdings (IART)
| -45.2 | -47.6 | -22.3 | -16.3 | 3.2 | 11.4 | 29.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Integra LifeSciences Holdings (IART)
|
16.7 | 1,300.4 | 1,647.7 | -7.2 | 5.8 | -0.7 | -- | 1.3 |
| 62.7 | 8,162.7 | 616.9 | -75.1 | 1.7 | -9.3 | -- | 10.0 | |
| 15.0 | 10,125.1 | 6,561.1 | -578.0 | -4.5 | -10.3 | -- | 1.8 | |
| 365.1 | 9,761.6 | 2,589.3 | 222.4 | -6.0 | 3 | 44.5 | 1.4 | |
| 58.5 | 8,913.0 | 3,499.6 | -71.2 | 0.5 | -3.2 | -- | 3.8 | |
| 177.5 | 10,637.8 | 612.8 | -188.1 | -30.6 | -28.1 | -- | 15.3 | |
| 101.0 | 6,590.6 | 1,556.3 | 275.3 | 24.6 | 22.9 | 24.2 | 5.0 | |
| 89.6 | 5,350.1 | 1,579.2 | 145.6 | 14.3 | 8.9 | 36.9 | 3.2 | |
| 322.2 | 12,649.5 | 1,504.9 | 160.6 | 13.6 | 10.9 | 79.3 | 8.3 | |
| 167.6 | 9,458.6 | 785.1 | 41.5 | 9.9 | 2 | 232.8 | 4.6 |
Shareholding Pattern
View DetailsAbout Integra LifeSciences Holdings (IART)
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty... Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey. Read more
-
Executive Chairman
Dr. Stuart M. Essig Ph.D.
-
Executive Chairman
Dr. Stuart M. Essig Ph.D.
-
Headquarters
Princeton, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Integra LifeSciences Holdings (IART)
What is the current share price of Integra LifeSciences Holdings (IART) Today?
The share price of Integra LifeSciences Holdings (IART) is $16.72 (NASDAQ) as of 04-Sep-2026 16:00 EDT. Integra LifeSciences Holdings (IART) has given a return of -26.87% in the last 3 years.
What is the current PB & PE ratio of Integra LifeSciences Holdings (IART)?
Since, TTM earnings of Integra LifeSciences Holdings (IART) is negative, P/E ratio is not available.
The P/B ratio of Integra LifeSciences Holdings (IART) is 1.25 times as on 04-Sep-2026, a 67 discount to its peers’ median range of 3.78 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.85 |
0.91 |
2024 |
-251.52 |
1.13 |
2023 |
50.36 |
2.15 |
2022 |
25.98 |
2.60 |
2021 |
33.99 |
3.41 |
What is the 52 Week High and Low of Integra LifeSciences Holdings (IART)?
The 52-week high and low of Integra LifeSciences Holdings (IART) are Rs 20.49 and Rs 8.70 as of 07-Sep-2026.
What is the market cap of Integra LifeSciences Holdings (IART)?
Integra LifeSciences Holdings (IART) has a market capitalisation of $ 1,300 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Integra LifeSciences Holdings (IART)?
Before investing in Integra LifeSciences Holdings (IART), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.